The BRAF V600E mutation, which is identified in approximately 80% of PTCs and 50% of ATCs in Japanese patients with thyroid cancer, drives tumorigenesis via MAPK pathway activation [2, 3]. This evidence concerns the gene BRAF and thyroid gland carcinoma.